Disclosures: Andrea Mospan: Nothing to Disclose, Breda Munoz: Nothing to Disclose, Heather Morris: Nothing to Disclose, Aarth Sheth: Nothing to Disclose, Rakesh Luthra: Nothing to Disclose 1080 VALIDATION AND EPIDEMIOLOGIC DEFINITION OF THE NOVEL STEATOTIC LIVER DISEASE NOMENCLATURE IN A NATIONAL COHORT WITH CIRRHOSIS Catherine Mezzacappa 1 Pedro Ochoa-Allemant 2 Marina Serper 3 Tamar Taddei 1 Binu John 4 David Kaplan 2 Nadim Mahmud 5 , 1 Yale University, 2 University of Pennsylvania, 3 University of Pennsylvania Health System, 4 University of Miami, 5 Hospital of the University of Pennsylvania Background: Novel steatotic liver disease (SLD) definitions were introduced in 2023 with a diagnostic algorithm based on the presence of cardiometabolic risk factors (CMRFs) and thresholds for alcohol exposure to define metabolic dysfunction-associated SLD (MASLD), alcohol-associated liver disease (ALD), and metabolic and alcohol-associated liver disease (MetALD)

Regulation [edit] G6PD converts G6P into 6-phosphoglucono--lactone and is the rate-limiting enzyme of the pentose phosphate pathway
Lorico, A
Vrije radicalen zijn instabiele moleculen die ontstaan door oxidatie en kunnen schade aanrichten aan je cellen
TABLE 1 Reported biological/immunomodulatory properties of MSI level 1 confirmed small molecules from helminths
L., Zhang J., Manevich Y., Townsend D